HF
TOVX icon

HRT Financial’s Theriva Biologics TOVX Stock Holding History

HRT Financial’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,142
Closed -$4K – 4042
2025
Q3 		$4K Buy
+10,142
New +$4.39K ﹤0.01% 2762
2024
Q4 		– Sell
-11,806
Closed -$16K – 3250
2024
Q3 		$16K Buy
+11,806
New +$57.6K ﹤0.01% 2207
2022
Q2 		– Sell
-408
Closed -$29K – 3732
2022
Q1 		$29K Buy
+408
New +$27.8K ﹤0.01% 2792
2021
Q4 		– Sell
-55
Closed -$6K – 4074
2021
Q3 		$6K Buy
+55
New +$6.84K ﹤0.01% 3199

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

HRT Financial's TOVX Position: Q4 2025 in Review

HRT Financial sold out of Theriva Biologics (TOVX) in Q4 2025, closing a stake of 10,142 shares — an estimated $4K sold.

HRT Financial first reported a position in TOVX in Q3 2021 and held it in 4 quarters. The position peaked at $29K in Q1 2022. 21 funds tracked by Wall St. Rank hold TOVX as of Q4 2025.

  • HRT Financial reported no remaining Theriva Biologics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 10,142 Theriva Biologics shares in Q4 2025, an estimated $4K.
  • HRT Financial first reported a position in Theriva Biologics in Q3 2021 and held it in 4 quarters.
  • HRT Financial's Theriva Biologics position peaked at $29K in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.